NasdaqCM - Nasdaq Real Time Price USD

Femasys Inc. (FEMY)

Compare
1.1900 0.0000 (0.00%)
At close: December 13 at 4:00:01 PM EST
1.1800 -0.01 (-0.84%)
After hours: 7:56:09 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Kathy Lee-Sepsick M.B.A. Founder, President, CEO & Director 804.67k -- 1968
Mr. Dov Elefant Chief Financial Officer 595.14k -- 1967
Mr. Daniel Scott Currie COO, Senior VP & Secretary 548.15k -- 1964
Ms. Mary An Merchant J.D., Ph.D. Vice President of Counsel & Intellectual Property -- -- --
Ms. Sue Owens Vice President of Sales -- -- --
Ms. Naomi Phaneuf Vice President of Marketing -- -- --
Dr. Jeffrey Marcus M.D., M.S. Chief Medical Advisor -- -- --
Ms. Christine Thomas Senior VP of Regulatory & Clinical Affairs -- -- 1973
Dr. James H. Liu M.D. Chief Medical Officer -- -- --
Mr. Richard Spector Chief Commercial Officer -- -- 1971

Femasys Inc.

3950 Johns Creek Court
Suite 100
Suwanee, GA 30024
United States
770 500 3910 https://www.femasys.com
Sector: 
Healthcare
Full Time Employees: 
32

Description

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Corporate Governance

Femasys Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

November 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 11, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 8, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 20, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 7, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

Related Tickers